
Novocure’s Q4 Disappointment: Missed Earnings and Revenue Estimates Explained
NovoCure’s Q3 Loss Widens: A Closer Look NovoCure (NVCR), a leading innovator in the field of cancer treatment using its proprietary technology, Tumor Treating Fields (TTFields), reported a wider-than-expected quarterly loss for Q3 2022. The loss amounted to $0.61 per share, which was a significant deviation from the Zacks Consensus Estimate of a loss of…